Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer.

Abstract

BACKGROUND:

Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity.

CASE PRESENTATION:

We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC.

RESULTS:

In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations.

CONCLUSION:

We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

• Authors: Ciliberto Domenico, Ierardi Antonella, Caroleo Benedetto, Scalise Luigi, Cimellaro Antonio, Colangelo Lidia, Spaziano Giuseppe, Luca Gallelli
• Journal: Current drug safety (Curr Drug Saf) Vol. 14 Issue 3 Pg. 233-237 ( 2019) ISSN: 2212-3911 [Electronic] United Arab Emirates
• PMID: 31113346 (Publication Type: Case Reports)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Organoplatinum Compounds
• Panitumumab
• Leucovorin
• Fluorouracil

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Colon, Descending
• Colonic Neoplasms (drug therapy)
• Female
• Fluorouracil (administration & dosage)
• Forearm (diagnostic imaging)
• Humans
• Leucovorin (administration & dosage)
• Middle Aged
• Organoplatinum Compounds (administration & dosage)
• Panitumumab (adverse effects)
• Panniculitis (chemically induced, diagnostic imaging)